Response to nitrazepam in infantile epileptic spasms syndrome after failed standard treatment
Epilepsy & Behavior · 2025-07 · 168 · 110418
DOI: 10.1016/j.yebeh.2025.110418 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsy & Behavior, 2025-07. Verfasst von Sunichaya Areekul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand. Hauptthemen laut MEDLINE: Spasms, Infantile, Anticonvulsants, Nitrazepam. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Over half of children with infantile epileptic spasms syndrome (IESS) do not respond to standard treatments. Nitrazepam has shown efficacy similar to adrenocorticotrophic hormone. This study evaluated response rates, adverse effects of nitrazepam, and factors associated with responders in children with IESS who failed standard treatment. METHODS: We conducted a retrospective observational study of children with IESS who failed standard treatments and subsequently received nitrazepam between January 1, 2013, and December 31, 2021. Responders were defined as those achieving sustained clinical resolution of epileptic spasms without relapse at the 3-month follow-up. Etiologies were classified according to the 2017 International League Against Epilepsy classification. RESULTS: The study included 85 children, with 26 (30.5 %) children showing a response to nitrazepam. Adverse effects occurred in 52 (61.2 %) children, with hypersalivation (47.1 %) being the most common. At the 12-month follow-up visit, 20 (23.5 %) children had sustained clinical resolution of epileptic spasms, with no recorded deaths. Etiology was known in 73.3 % (structural 52 %; infectious 10.7 %; genetic 8 %; metabolic 2.7 %) and unknown in 26.7 %. Known etiology increased the likelihood of responding to nitrazepam (adjusted OR 5.78, 95 % CI 1.17, 28.72, p = 0.032), while a longer duration from epileptic spasms onset to nitrazepam decreased the odds of response (adjusted OR 0.85, 95 % CI 0.74, 0.98, p = 0.021). CONCLUSION: Approximately, 31% of children responded to nitrazepam. Early initiation of treatment with nitrazepam may be beneficial for children with IESS, particularly those with a known etiology, after failure of standard treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand.
- Department of Pediatrics, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand; College of Medicine, Rangsit University, Bangkok, Thailand.
- Department of Pharmacy, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand.
- Department of Pediatrics, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand; College of Medicine, Rangsit University, Bangkok, Thailand. Electronic address: kullasate.s@rsu.a…
Zitieren
APA
Areekul, S., Suwannachote, S., Boonkrongsak, R., Sri-Udomkajorn, S., Wittawassamrankul, R., & Sakpichaisakul, K. (2025). Response to nitrazepam in infantile epileptic spasms syndrome after failed standard treatment. Epilepsy & Behavior, 168, 110418. https://doi.org/10.1016/j.yebeh.2025.110418
Vancouver
Areekul S, Suwannachote S, Boonkrongsak R, Sri-Udomkajorn S, Wittawassamrankul R, Sakpichaisakul K. Response to nitrazepam in infantile epileptic spasms syndrome after failed standard treatment. Epilepsy & Behavior. 2025;168:110418. doi:10.1016/j.yebeh.2025.110418
BibTeX
@article{Areekul2025,
author = {Areekul, Sunichaya and Suwannachote, Sirorat and Boonkrongsak, Rachata and Sri-Udomkajorn, Somjit and Wittawassamrankul, Raviwan and Sakpichaisakul, Kullasate},
title = {Response to nitrazepam in infantile epileptic spasms syndrome after failed standard treatment},
journal = {Epilepsy & Behavior},
year = {2025},
volume = {168},
pages = {110418},
doi = {10.1016/j.yebeh.2025.110418}
}
EUVIMED